Clin Osteol 2012; 17(4): 128-135

Limited walking ability significantly contributes to a loss of bone mineral density in the proximal femur in premenopausal and postmenopausal women with multiple sclerosisReview articles

I. Raška jr., M. Týblová, M. Rašková, D. Michalská, E. Havrdová, V. Zikán

The aim of the study was to assess changes in bone mineral density (BMD) in relation to VDR gene polymorphisms (Bsm-I and Fok-I), motor deficit and glucocorticoid treatment in multiple sclerosis (MS) patients without osteoporosis supplemented with vitamin D and calcium and MS patients with osteoporosis treated with risedronate. A total of 165 women treated with low-dose glucocorticoids without osteoporosis and 34 patients with newly diagnosed osteoporosis and newly treated with risedronate were included in this lon­ gitudinal study. The Expanded Disability Status Scale (EDSS) score was less than 6.5 in all patients. After 2-year observation, women supplemented with vitamin D and calcium did not show any significant changes in BMD or markers of bone remodeling. Patients treated with risedronate showed statistically significant increases in BMD in the lumbar spine (p < 0.001) and reduction in bone re­ modeling markers (p < 0.001). In either the entire studied sample or within each group, there was no association between VDR gene polymorphisms and parameters of bone metabolism (initial BM and BMD and their changes after 12- and 24-month follow-up, res­ pectively). Initial BMD and score in each studied group.

Conclusion: Limited walking ability in patients with MS significantly contributes to the loss of BMD in the total hip in patients sup­ plemented with calcium and vitamin D and also in patients with osteoporosis treated with risedronate. VDR gene polymorphisms, 25-OH vitamin D levels or low-dose glucocorticoid treatment had no significant effect on changes in BMD after 2-year follow-up.

Keywords: multiple sclerosis, osteoporos

Published: December 11, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Raška I, Týblová M, Rašková M, Michalská D, Havrdová E, Zikán V. Limited walking ability significantly contributes to a loss of bone mineral density in the proximal femur in premenopausal and postmenopausal women with multiple sclerosis. Osteologický bulletin. 2012;17(4):128-135.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Compston A, Coles A Multiple sclerosis. Lancet 2008;372(9648):1502-1517. Go to original source...
    2. Sibley WA, Bamford CR, Clark K, Smith MS, Laguna JF. A prospective study physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 1991; 54(7):584-589. Go to original source...
    3. Troiano RA, Jotkowitz A, Cook SD, Bansil S, Zito G. Rate and types of fra in corticosteroid-treated multiple sclerosis patients. Neurology 1992;42(7): 1389-1391. Go to original source...
    4. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitam deficiency and reduced bone mass in multiple sclerosis. Neurology 1994;44(9): 1687-1692. Go to original source...
    5. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients ex Miner Res 1994;9(7):1097-1105. Go to original source...
    6. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C et al. Fracture h tory and bone loss in patients with MS. Neurology 1998;51(4):1161-1165. Go to original source...
    7. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of am­ bulatory status and functional capacity. J Bone Miner Metab 2005;23(4):309-313. Go to original source...
    8. Havrdová E, Týblová M, Štěpán J, Horáková D, Tichá V, Nováková I, Zelená L, Zikán V, Hlásenská J. Výskyt osteoporózy u pacientů s roztroušenou sklerózou v závislosti na míře kortikoterap Neurochir 2004;67/100(4):234-240.
    9. Kurtzke JF. Rating neurologic impairment in multiple sclero sability status scale (EDSS). Neurology 1983;33(11):1444-1452. Go to original source...
    10. Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K et Risk of bone loss in men with multiple sclerosis. Mult Scler 2004;10(2):170-175. Go to original source...
    11. Schwid SR, Goodman AD, Edward PJ, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996;53(8):753-757. Go to original source...
    12. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of am­ bulatory status and functional capacity. J Bone Miner Metab 2005; 23(4):309-313. Go to original source...
    13. Terzi T, Terzi M, Tander B, Canturk F, Onar M. Changes in bone mineral densi­ ty and bone metabolism markers in premenopausal women with multiple sclero­ sis and the relationship to clinical variables. J Clin Neurosci 2010;17(10): 1260-1264. Go to original source...
    14. Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone hea in multiple sclerosis. Neurology 2009;73(17):1394-1398. Go to original source...
    15. Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects o glucocorticoid use. Calcif Tissue Int 1997;61(2):129-133. Go to original source...
    16. Moen SM, Celius EG, Sandvik L, Nordsletten L, Eriksen EF, Holm0y T. Low bo­ ne mass in newly diagnosed mu Neurology 2011;77(2):151-157. Go to original source...
    17. Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG. Predicting accidental falls in peopl 259-269.
    18. Finlayson ML, Peterson EW, Cho CC. Risk factors for falling among people a 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil 2006;87(9): 1274-1279. Go to original source...
    19. Dawson-Hughes B, Harris SS, Finneran S. Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J Clin Endocrinol Metab 1995;80(12):3657-3661. Go to original source...
    20. Riggs BL, Nguyen TV, Melton LJ 3rd, Morrison NA, O'Fallon WM, Kelly PJ KS, Sambrook PN, Muhs JM, Eisman JA The contribution of vitamin D receptor gene alleles to the determination of bone mineral rotic women. J Bone Miner Res 1995;10(6):991-996. Go to original source...
    21. Fang Y, van Meurs JB, Rivadeneira F, van Schoor NM, van Leeuwen JP, Lips P, Pols HA, Uitterlinden AG. Vitamin D receptor gene haplotype is associate body height and bone size. J Clin Endocrinol Metab 2007;92(4):1491-1501. Go to original source...
    22. Tokita A, Matsumoto H, Morrison NA, Tawa T, Miura Y et al. Vitamin D recep­ tor alleles, bone mineral density and J Bone Miner Res 1996;11(7):1003-1009. Go to original source...
    23. Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Reeve J, Reid DM, Amedei A, Bassit Bustamante M, Husted LB, Diez-Perez A, Dobnig H, Dunning AM, Enjuanes A, Fahrleitner-Pammer A, Fang Y, Karczmarewicz E, Kruk M, van Leeuwen JP, Mavilia C, van Meurs JB, Mangion J, McGuigan FE, Pols HA, Renner W, Rivadeneira F, van Schoor NM, Scollen S, Sherlock RE, Ioannidis JP; APOSS Investigators; EPOS Investigators; EPOLOS Investigators; FAMOS Investigat LASA Investigators; Rotterdam Study Investigators; GENOMOS Study. The as­ sociation between common vitamin D receptor gene variations and osteop a participant-level meta-analysis. Ann Intern Med 2006;145(4):255-264. Go to original source...
    24. Grundberg E, Brändstrom H, Ribom EL, Ljunggren O, Mallmin H, Kindmark A Genetic variation in the human vitamin D receptor is associated with muscle strength, fat m 150(3):323-328.
    25. Smolders J, Damoiseaux J, Menheere P, Tervaert JW, Hupperts R. Fok-I vi min D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol 2009;15;207(1-2):117-121. Go to original source...
    26. Mamutse G, Woolmore J, Pye E, Partridge J, Boggild M, Young C, Fryer A, Hoban PR, Rukin N, Alldersea J, Strange RC, Hawkins CP. Vitamin D receptor gene polymorphism is associated Mult Scler 2008;14(9):1280-1283. Go to original source...
    27. Sioka C, Ppakonstantinou S, Markoula S, Gkartziou F, Georgiou A, Georgi Pelidou SH, Kyritsis AP, Fotopoulos A Vitamin D receptor gene polymorphisms in multiple sclerosis patients in northwest Greece. J Negat Results Biomed 20 10:3.
    28. Mok CC, Tong KH, To CH, Siu YP, Ma KM. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a r double-blind placebo-controlled trial. Osteoporos Int 2008;19(3):357-364. Go to original source...
    29. Jiang SD, Dai LY, Jiang LS. Osteoporosis after spinal cord injury. Osteoporo 2006;17(2):180-192. Go to original source...
    30. Slade JM, Bickel CS, Modlesky CM, Majumdar S, Dudley GA Trabecular bone is more deteriorated in spinal cord injured versus estrogen-free postmenopausal women. Osteoporos Int 2005;16(3):263-272. Go to original source...
    31. Jorgensen L, Jacobsen BK, Wilsgaard T, Magnus JH. Walking after stroke: does it matter? Changes in bone mineral density within the fi A longitudinal study. Osteoporos Int 2000;11(5):381-387. Go to original source...
    32. Martyn-St James M, Carroll S. Meta-analysis of walking for pr mineral density in postmenopausal women. Bone 2008;43(3):521-531. Go to original source...
    33. Ryan AS, Ivey FM, Hurlbut DE, Martel GF, Lemmer JT, Sorkin JD et al. Regional bone mineral density after resistive tra Scand J Med Sci Sports 2004;14(1):16-23. Go to original source...
    34. Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C et al. Resistance training improves muscle strengt sclerosis. Neurology 2009;73(18):1478-1484. Go to original source...
    35. Snook EM, Motl RW. Effect of exercise training on walking mobility in m sclerosis: a meta-analysis. Neuro rehabil Neural Repair 2009;23(2):108-116. Go to original source...
    36. Kiel DP, Myers RH, Cupples LA, Kong XF, Zhu XH, Ordovas J, Schaefer EJ, Felson DT, Rush D, Wilson PW, Eisman JA, Holick MF. The BsmI vitamin D re­ ceptor restriction fragment length polymorphism (bb) influences the effect cium intake on bone mineral density. J Bone Miner Res 1997;12(7):1049-1057. Go to original source...
    37. Michaelsson K, Wolk A, Jacobsson A, Kindmark A, Grundberg E, Stiger F, Mallmin H, Ljunghall S, Melhus H. The positive effect of dietary vitamin D inta­ ke on bone mineral density in men is modulated by the polyadenosine repeat lymorphism of the vitamin D receptor. Bone 2006;39(6):1343-1351. Go to original source...
    38. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Re 2003;18(1):192-198. Go to original source...
    39. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship wit Clin Endocrinol (Oxf) 2003;58(3):365-371. Go to original source...
    40. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT et al. Prevale of Vitamin D inadequacy among postmenopausal North American women recei­ ving osteoporosis therapy. J Clin Endocrinol Metab 2005;90(6):3215-3224. Go to original source...
    41. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vi­ tamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009;169(6):626-632. Go to original source...
    42. Yildiz M, Tettenborn B, Putzki N. V tients. Swiss Med Wkly 2011;141:w13192. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.